Replies to post #29069 on Marker Therapeutics Inc (MRKR)

[Gatta-git-it]

Pl, my friend. We have for a long time. Ow either agreed on items or respectfully disagreed, always in a healthy manner and always seeking the best outcome.

To the point, no, I don't think 2 or 3 times a year is sufficient. On the contrary, other bio tech companies do communicate issues and successes more frequently.

We have been taken down from a high of ~ $9.00 to where we are because of mistakes by management. A management with brilliant scientific knowledge, skills, and connections. Two departments are weak... Law, and Finance with HR. External communications are a part of and prepared by them. My opinion. Market reflection.

[lumpy9200]

I just want to understand what everyone else's expectations are

My expectations are quite simple, though I may be in the minority. For me, I expect the clinical trials for MultiTAA to keep going, get finished in whatever time is needed to get them done, and then eventually we'll get FDA approval when all is said and done (and perhaps partners for specific indications along the way). That's it. So essentially I just expect the company to do what they've been doing. If any Tapimmune drugs aren't worth continuing on in clinical trials, they'll stop. Just like they did. My expectation when I first invested in MRKR was a $25-30 stock a few years down the road, based solely on AML. With the addition of solid types of cancers, my expectation has gone up to $50+ per share. There isn't one thing that has happened that's changed my view. I continue to believe that despite charts, technicals, shorts and every other negative that gets thrown around, the science here will win the day. Exactly nothing has changed my mind on that. MultiTAA is one of the most amazing and incredible things to ever come out of the I/O space, and this company needs to just keep on doing what they're doing.

I also think some people here expect biotech researchers to be as polished on the business side as a career "businessman" would be. I don't think life works like that. Marker may not have had the best CC the other day, but that isn't ever going to be the company's strongest area. And that's a good thing. I want brilliant biotech researchers running this company, and I think we have that. If that means they aren't also great at delivering at conference calls, I'll take it. I personally believe that anyone calling for Peter's head is extremely misguided. Peter will be overseeing a multi-billion company soon enough, and we'll get there in part because of him, not in spite of him.

No one needs a speech from me, but investing in biotechs isn't ever a quick gain with no headaches. It comes with the territory. MRKR is dealing with things that so many other biotechs have faced before them. And so many will in the future. But they don't have a drug that will bomb in a Phase 3 trial and shave 75% off the stock price. Patient investors will be richly rewarded. And that's all I've ever expected from the company.